Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

REG

An independent study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery, conducted at Nottingham Children’s Hospital, shows positive results for Epiprotect®. The study highlights significant pain relief, safety, and quick and easy patient follow-ups. Involving 99 patients aged 0 - 18 years treated for partial-thickness burns, the study reveals that Epiprotect® has comparable acute healing outcomes to Biobrane® from Smith & Nephew, but with a significantly lower infection rate (2.6% compared to 16.4%).

"It is highly significant for S2Medical that high-quality studies like this confirm the benefits we have experienced during our journey to introduce Epiprotect® to the global market. That Epiprotect® now proves to reduce infection risks compared to one of the previously leading products is an enormously important finding, especially since infections in children can mean the difference between life and death," says the company's CEO, Petter Sivlér.

The company expects that the results will accelerate the commercialization of Epiprotect products, leading to increased royalty revenues and enhancing the potential for additional payments for Epiprotect.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2024 10:32 CET.

Datum 2024-06-20, kl 10:32
Källa Cision
Bifogade filer
Alla Aktier tipsar: Nu får du 200 kr gratis när du skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra tillfälle för dig som inte kommit igång med investeringar än, eller bara testat t.ex. Avanza.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet